Cargando…
O-GlcNAc Transferase Inhibitor Synergistically Enhances Doxorubicin-Induced Apoptosis in HepG2 Cells
SIMPLE SUMMARY: We found that the combination treatment of doxorubicin (DOX) and O-GlcNAc transferase (OGT) inhibitor OSMI-1 has synergic therapeutic efficacy in the treatment of liver cancer. Our data show that DOX displayed cytotoxicity via the activation of p53 and the inflammatory NF-κB signalin...
Autores principales: | Lee, Su Jin, Kwon, Oh-Shin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693581/ https://www.ncbi.nlm.nih.gov/pubmed/33121131 http://dx.doi.org/10.3390/cancers12113154 |
Ejemplares similares
-
X-inactivation normalizes O-GlcNAc transferase levels and generates an O-GlcNAc-depleted Barr body
por: Olivier-Van Stichelen, Stéphanie, et al.
Publicado: (2014) -
Feedback Regulation of O-GlcNAc Transferase through Translation Control to Maintain Intracellular O-GlcNAc Homeostasis
por: Lin, Chia-Hung, et al.
Publicado: (2021) -
A Conserved Splicing Silencer Dynamically Regulates O-GlcNAc Transferase Intron Retention and O-GlcNAc Homeostasis
por: Park, Sung-Kyun, et al.
Publicado: (2017) -
Proteolysis of HCF-1 by Ser/Thr glycosylation-incompetent O-GlcNAc transferase:UDP-GlcNAc complexes
por: Kapuria, Vaibhav, et al.
Publicado: (2016) -
Structural insights into mechanism and specificity of O-GlcNAc transferase
por: Clarke, Andrew J, et al.
Publicado: (2008)